Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):478.
doi: 10.21037/atm.2017.11.02.

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial

Rikke Borg  1   2 , Frederik Persson  3
Affiliations
Editorial

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial

Rikke Borg et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: R Borg reports having received lecture fees from Novartis, Amgen, Gambro, and Novo Nordisk and having served as a consultant for Boehringer Ingelheim and Astra Zeneca. F Persson reports having received research grants from AstraZeneca and Novartis and lecture fees from Novartis, Eli Lilly, MSD, AstraZeneca, Sanofi and Boehringer Ingelheim and having served as a consultant for Astra Zeneca, Bayer, Amgen, Novo Nordisk and MSD.

Comment on

Similar articles

See all similar articles

References

    1. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 2015;107:1-8. 10.1016/j.diabres.2014.10.014 - DOI - PubMed
    1. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8. 10.1056/NEJMoa011489 - DOI - PubMed
    1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. 10.1056/NEJMoa011161 - DOI - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. 10.1056/NEJMoa011303 - DOI - PubMed
    1. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. 10.1111/j.1523-1755.2004.00653.x - DOI - PubMed

LinkOut - more resources